<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230606058389N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-07-10</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>The effect of epinephrine nebulizer with subcutaneous injection in patients with acute asthma attack</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of epinephrine nebulizer with subcutaneous injection in patients with acute asthma attack: a randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-07-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>66</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70513</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Blocked randomization
Exactly equal number of participants are included in the intervention and control group at consecutive but equal time intervals. And blocks of four will be used.
The sequences will be placed in the envelopes in the package. The appearance of the envelopes is such that their contents cannot be seen from the outside. Then, one of the envelopes will be opened for each patient entered into the plan and based on the contents of the envelope, the patient will be entered into one of the control or intervention groups, Blinding description: The sequences will be placed in the envelopes in the package. The appearance of the envelopes is such that their contents cannot be seen from outside. Then, one of the envelopes will be opened (in order) for each patient entered into the plan and based on the contents of the envelope, the patient will be entered into one of the control or intervention groups.</study_design>
      <phase>2</phase>
      <hc_freetext>Status asthma.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Children with an acute asthma attack that has not responded to standard treatments. Children with an acute attack referred to the emergency room of Akbar, Qaim or Sheikh Children's Hospitals who have not responded to the initial stages of standard asthma treatment including bronchodilator oxygen, Atrovent, and injectable corticosteroids with appropriate doses, and due to the persistence of respiratory symptoms and wheezing Inclusion criteria are included in the treatment process. After obtaining written informed consent from parents or legal guardians and under subcutaneous injection of epinephrine with a dose of 0.01 cc of 1.1000 solution or epinephrine nebulization in the form of nebulization of two ampoules of epinephrine 1.1000 which after adding normal saline reached the appropriate volume for nebulization will be placed. The procedures will be performed under the supervision of the resident guard of the hospital and according to the standard instructions, which will be performed between the time of visit and one hour after receiving subcutaneous epinephrine. The stages of recovery of asthma symptoms will be checked and recorded according to the pulmonary index score table. Then the symptoms will be checked until the end of the complete recovery and the time to reach this condition for both groups will be recorded in the checklist prepared for this purpose. Intervention 2: Control group: Children with an acute attack of severe asthma and resistant to the standard early stages of asthma treatment (including: oxygen therapy, nebulized bronchodilator, Atrovent, injectable corticosteroids) treated with standard asthma treatment and subcutaneous epinephrine ampoules 1.1000 with dosage CC 0.01. The continuation of the treatment process, such as the intervention group, will be carefully checked and recorded by the hospital resident and relevant specialist at intervals upon entering the hospital and according to the table.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is After the end of the research and the agreement of the research team, a decision will be made to share non-identifiable data.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyed Javad Seyedi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Akbar hospital, Kaveh-14 blvd.</address>
        <city>Mashahd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177897157</zip>
        <telephone>+98 910 171 6090</telephone>
        <email>mobinmdl94@gmail.com</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyed Javad Seyedi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Akbar hospital, Kaveh-14 blvd.</address>
        <city>Mashahd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177897157</zip>
        <telephone>+98 910 171 6090</telephone>
        <email>mobinmdl94@gmail.com</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children with acute asthma attacks referred to the emergency of Akbar's children, Qaem or Dr. Sheikh hospitals who have not responded to the initial stages of standard asthma treatment, including bronchodilator oxygen, Atrovent, and injectable corticosteroids with appropriate doses.</inclusion_criteria>
      <agemin>2 years</agemin>
      <agemax>14 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Children with asthma with conventional treatment response
Children over 14 years old
Children with asthma due to another side effect</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J45.902</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Unspecified asthma with status asthmaticus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Children with an acute asthma attack that has not responded to standard treatments. Children with an acute attack referred to the emergency room of Akbar, Qaim or Sheikh Children's Hospitals who have not responded to the initial stages of standard asthma treatment including bronchodilator oxygen, Atrovent, and injectable corticosteroids with appropriate doses, and due to the persistence of respiratory symptoms and wheezing Inclusion criteria are included in the treatment process. After obtaining written informed consent from parents or legal guardians and under subcutaneous injection of epinephrine with a dose of 0.01 cc of 1.1000 solution or epinephrine nebulization in the form of nebulization of two ampoules of epinephrine 1.1000 which after adding normal saline reached the appropriate volume for nebulization will be placed. The procedures will be performed under the supervision of the resident guard of the hospital and according to the standard instructions, which will be performed between the time of visit and one hour after receiving subcutaneous epinephrine. The stages of recovery of asthma symptoms will be checked and recorded according to the pulmonary index score table. Then the symptoms will be checked until the end of the complete recovery and the time to reach this condition for both groups will be recorded in the checklist prepared for this purpose.</i_keyword>
      <i_keyword>Control group: Children with an acute attack of severe asthma and resistant to the standard early stages of asthma treatment (including: oxygen therapy, nebulized bronchodilator, Atrovent, injectable corticosteroids) treated with standard asthma treatment and subcutaneous epinephrine ampoules 1.1000 with dosage CC 0.01. The continuation of the treatment process, such as the intervention group, will be carefully checked and recorded by the hospital resident and relevant specialist at intervals upon entering the hospital and according to the table.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Number of breaths per minute according to age,. Timepoint: The time interval before the visit and one hour after receiving subcutaneous epinephrine or epinephrine bolus. Patients will be visited and examined by the on-call resident during their hospitalization. Method of measurement: Subcutaneous injection of epinephrine with a dose of 0.01 cc of 1.1000 solution or nebulization of epinephrine in the form of nebulization of two ampoules of epinephrine 1.1000 which will be placed after adding normal saline to the appropriate volume for nebulization.</prim_outcome>
      <prim_outcome>Expiratory - inspiratory wheezing. Timepoint: The time interval before the visit and one hour after receiving subcutaneous epinephrine or epinephrine bolus. Patients will be visited and examined by the on-call resident during their hospitalization. Method of measurement: Subcutaneous injection of epinephrine with a dose of 0.01 cc of 1.1000 solution or nebulization of epinephrine in the form of nebulization of two ampoules of epinephrine 1.1000 which will be placed after adding normal saline to the appropriate volume for nebulization.</prim_outcome>
      <prim_outcome>Use of respiratory secondary muscles. Timepoint: The time interval before the visit and one hour after receiving subcutaneous epinephrine or epinephrine bolus. Patients will be visited and examined by the on-call resident during their hospitalization. Method of measurement: Subcutaneous injection of epinephrine with a dose of 0.01 cc of 1.1000 solution or nebulization of epinephrine in the form of nebulization of two ampoules of epinephrine 1.1000 which will be placed after adding normal saline to the appropriate volume for nebulization.</prim_outcome>
      <prim_outcome>Oxygen saturation according to the Pulmonary Index score table. Timepoint: The time interval before the visit and one hour after receiving subcutaneous epinephrine or epinephrine bolus. Patients will be visited and examined by the on-call resident during their hospitalization. Method of measurement: The treatment steps for asthma symptoms will be carefully checked and recorded according to the pulmonary index score table. Then the symptoms will be checked until the end of the complete recovery and the time to reach this condition for both groups will be recorded in the checklist prepared for this purpose.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-04-24</approval_date>
        <contact_name>Ethics Committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Mashhad, Daneshgah Street, next to Hoizeh Cinema, Qorshi Building, Research and Technology Vice-Chancellor Mashahd Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
